PharmaCCX announces Mark Trusheim joining as member of Advisory Board

September 13, 2021

PharmaCCX is pleased to announce that Mark Trusheim has joined the company's advisory board where he will advise on the company's strategy based on his experience on both the private and government side of life sciences.

Mark is currently the Strategic Director at MIT NEWDIGS where he also co-leads the Financing and reimbursement of Cures in the US (FoCUS) Project and is a visiting Scientist at the MIT Sloan School of Management.

Nathan Sigworth, PharmaCCX's co-founder and CEO said "I am looking forward to working with Mark on several areas of our business. Mark's insights to how treatments are priced and the evolving financing and reimbursement landscape will help us build a better product to address the needs of both payers and pharma, and consequently have a positive impact on patients."

Mark's research focuses on the economics of biomedical innovation, especially precision financing for patient access, precision medicine, adaptive pathways, platform trials, biosimilars, and digital health advances.

"I look forward to working with Nathan and the team at PharmaCCX" said Trusheim. "It is exciting to see areas I've studied for years as part of my research being pushed to new limits using a technology solution"

Mark is also President of Co-Bio Consulting, LLC. Prior to MIT, his career spanned big data at Kenan Systems, marketing at Searle Pharmaceuticals, eHealth as Vice President of Monsanto Health Solutions, genomics as President of Cereon Genomics, and policy as the President of the Massachusetts Biotechnology Council. He holds degrees in Chemistry from Stanford University and Management from MIT.